Business Overview

DexCom is a medical device company built almost entirely around continuous glucose monitoring (CGM), a technology that tracks a person's glucose levels in real time using a small sensor worn on the body. Each system pairs a disposable sensor and transmitter with a receiver or, more commonly today, a smartphone app, giving people with diabetes a continuous stream of readings and trend alerts instead of the single snapshot a finger-stick provides. The company's product line has evolved through successive generations (the G-series, including the G6 and G7) and, more recently, into over-the-counter products aimed at people who do not use insulin, such as the Stelo biosensor. DexCom sells globally, with a large U.S. base and a growing international footprint across Europe, Asia-Pacific, and other markets.

The core of the business model is a razor-and-blade dynamic: the durable or reusable components draw a user in, but the recurring revenue comes from disposable sensors that must be replaced on a regular cycle (every several days to a couple of weeks depending on the product). Because a person with diabetes typically uses the system continuously, each new patient becomes a stream of repeat consumable purchases that can last for years. Revenue flows through several channels, including durable medical equipment distributors, retail and mail-order pharmacies, and direct relationships with patients, and is heavily influenced by what private insurers, Medicare, and international health systems agree to reimburse. In short, DexCom makes money by converting newly diagnosed and newly covered diabetes patients into long-term, recurring buyers of sensor consumables.

Financial Trends

DexCom's financial profile is that of a high-growth, high-gross-margin medical device franchise built on recurring consumables. The dominant growth drivers to think about are new patient additions (especially as CGM expands from insulin-using type 1 and type 2 patients toward the much larger basal and non-insulin populations), expansion of insurance and Medicare coverage, and international market penetration. Because sensors are consumables, the installed base of users tends to compound revenue over time even before new launches.

• Gross margin: Hardware-style economics with software-style stickiness — gross margins are typically high for a device maker, and shifts in product mix, manufacturing yield, and scale can move them meaningfully. The transition to newer sensor platforms (which are generally cheaper to produce at scale) is a recurring margin theme.
• Operating costs: The company invests heavily in sales and marketing (to win patients and prescribers) and in R&D (to advance sensor accuracy, wear time, and new products). These line items shape how much of revenue growth reaches the bottom line.
• Capital intensity: Scaling sensor manufacturing requires ongoing capital expenditure on automated production capacity, so capex and the resulting depreciation are worth tracking.
• Cash generation and balance sheet: As a maturing growth company, DexCom generates operating cash flow and carries convertible debt; investors often watch its cash position, debt structure, and any share-repurchase activity.

The general story is one of strong top-line growth with margins and profitability that depend on product mix, manufacturing efficiency, and how aggressively the company spends to capture a still-largely-untapped market.

What to Watch in the Filings

Because so much of the thesis rests on volume and pricing of a single product category, DexCom's filings reward close reading of a few specific areas:

• Revenue disaggregation: The split between U.S. and international (OUS) revenue, and any commentary on new-patient growth versus existing-base reorders. International is often the faster-growing piece.
• Per-unit pricing dynamics: Management routinely discusses how channel mix (pharmacy vs. DME), rebates, and a shift toward newer, lower-priced sensors affect average selling price. Watch MD&A for "volume up, price down" commentary, which is common in CGM.
• Gross margin bridge: Explanations of margin changes tied to manufacturing yields, new sensor ramp costs, and scrap or warranty reserves.
• Coverage and reimbursement news: 8-K filings and earnings commentary on Medicare rules, formulary placement, and new-country reimbursement wins or losses.
• New product and OTC traction: Disclosures on G7 adoption and on the over-the-counter Stelo line, which targets a different (often cash-pay) customer than the traditional insulin-using base.
• Guidance and revisions: DexCom is a stock where revenue and margin guidance changes drive large reactions; 8-Ks and earnings releases are the place to track raises or cuts and the reasons given.
• Convertible debt and share count: Footnotes on convertible notes, related hedges, and dilution, plus any buyback authorizations.

Key Risks

• Competition: The CGM market is intensely competitive, most directly with Abbott's FreeStyle Libre franchise, and increasingly with new entrants and integrated insulin-delivery players. Pricing pressure and share shifts are persistent threats.
• Reimbursement and pricing: Revenue depends heavily on coverage decisions by private insurers, Medicare, and foreign health systems. Adverse rate changes, formulary exclusions, or a faster-than-expected shift to lower-priced sensors can compress average selling price.
• Product concentration: The company is essentially a single-category business; any setback in CGM sensors — accuracy issues, recalls, or a competing technology — would hit nearly all of revenue.
• Manufacturing and supply chain: Scaling sensor production is complex; yield problems, component shortages, or quality issues can disrupt supply and dent margins.
• Regulatory: As FDA-regulated devices, products face clearance/approval requirements, post-market surveillance, recall risk, and quality-system inspections; delays in new-generation approvals can stall the roadmap.
• Execution and expectations: As a high-multiple growth stock, DexCom is sensitive to any deceleration in patient growth or guidance, which can drive sharp share-price moves disconnected from a single quarter's economics.
• International and currency: Growing OUS exposure brings foreign-exchange volatility and country-specific reimbursement and competitive dynamics.
• Litigation and IP: The company is involved in patent and other litigation typical of a leading device maker, which carries financial and competitive uncertainty.

Frequently Asked Questions